Effects of Agomelatine on Sleep Across Populations: A Systematic Review and Meta-Analysis
Abstract
Agomelatine, a melatoninergic antidepressant, is often prescribed to improve sleep disturbance, though meta-analytic evidence is currently lacking. This systematic review and meta-analysis assessed its efficacy and tolerability in sleep outcomes compared to placebo. We systematically searched clinical trial registries (Cochrane Central, WHO ICTRP, ClinicalTrials.gov) and databases (MEDLINE, Embase, APA PsycINFO) up to February 16, 2025, for Randomised Controlled Trials (RCTs) comparing agomelatine with placebo that reported sleep-related outcomes. Analyses were conducted using a random-effects model on an intention-to-treat basis. Risk ratios (RR) were used for dichotomous outcomes, weighted mean differences (WMD) for continuous outcomes, and Hedge's adjusted g (SMD) when different scales were used. Primary outcomes included subjective and objective total sleep time, subjective sleep quality, and treatment-emergent somnolence and insomnia. Subgroup and sensitivity analyses explored heterogeneity and assessed robustness. Twenty-five RCTs with 6812 participants were included. No significant effect was found for objective total sleep time (MD = -15.73 min, 95% CI: -49.68; 18.22), while subjective sleep quality improved more with agomelatine than placebo (SMD = 0.31, 95% CI: 0.21; 0.40). Agomelatine was associated with fewer incidents of insomnia (RR = 0.59, 95% CI: 0.39; 0.90) but more incidents of somnolence (RR = 1.34, 95% CI: 1.02; 1.75). Agomelatine was found to cause…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 6,812 participants or records.
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.